Piramal Pharma has awarded its integrated media mandate to OMD India, part of Omnicom Media Group, following a multi-round pitch to handle the mandate of scaling the brand through sharp, creative and forward-leaning communication efforts.
As part of the mandate win, OMD India will spearhead the strategic marketing and media efforts for Piramal Pharma’s portfolio of OTC brands, including Lacto Calamine, Little’s, Tetmosol, Polycrol, and Women’s intimate health range like i-pill and i-activ, and will be managed out of the agency’s Mumbai office.
Known for its media and digital innovation prowess, OMD India will be responsible for deploying an efficient game plan to enhance Piramal Pharma’s presence across markets, boost brand salience, drive consumer engagement, and enable impact-driven marketing strategy to be a driver for business growth.
Commenting on the mandate win, Anisha Iyer, CEO, OMD India, said, “We are excited to embark on this partnership with Piramal Consumer Healthcare, a company that mirrors our commitment to innovation and excellence.”
“This collaboration presents a significant opportunity to leverage our strategic acumen and deep market intelligence to elevate Piramal’s impressive portfolio of brands to new heights. Together, we aim to craft media strategies that go beyond visibility—building lasting trust and loyalty with consumers across India and shaping a future of sustained growth and impact,” she added.
